Truvada News and Research RSS Feed - Truvada News and Research

Study provides new insights into real-world use of PrEP

Study provides new insights into real-world use of PrEP

Several studies presented today in an official press conference at the 21st International AIDS Conference in Durban provided new insights on the use of PrEP among a broad range of populations. [More]
Study confirms efficacy of PrEP in reducing risk of HIV infection in men who have sex with men

Study confirms efficacy of PrEP in reducing risk of HIV infection in men who have sex with men

The last phase of ANRS IPERGAY has confirmed that "on-demand" pre-exposure prophylaxis (PrEP) is a highly effective method of reducing the risk of HIV infection in men who have sex with men and who report high-risk behavior. [More]
HOPE study seeks to understand safety of vaginal ring in protecting women against HIV

HOPE study seeks to understand safety of vaginal ring in protecting women against HIV

Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE. [More]
Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

A Houston Methodist research team received a nearly $4 million grant to test a transcutaneously refillable implant that administers pre-exposure prophylaxis drugs to subjects at risk of HIV-exposure. [More]
NHS England takes too long to commission PrEP for HIV prevention

NHS England takes too long to commission PrEP for HIV prevention

An effective treatment that can prevent HIV infection and reduce the human and financial costs of the preventable condition is taking too long to be commissioned and made available on the NHS, warns Deborah Gold, chief executive of the National Aids Trust, in an article published by The BMJ today. [More]
Women need antiviral medication Truvada more than men to prevent HIV infection

Women need antiviral medication Truvada more than men to prevent HIV infection

Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill. [More]
Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV. [More]
Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from phase 3 women-only HIV study show improved safety, efficacy of Stribild drug

Results from the first phase 3 HIV study to enroll only women show improved safety and efficacy of the drug Stribild over multi-pill antiretroviral drug regimens. The research was presented at ASM's 55th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC/ICC). [More]
HIV prevention program undergoes “real world” evaluation

HIV prevention program undergoes “real world” evaluation

A programme that provides pre-exposure prophylaxis (PrEP) to prevent HIV infection among sexually active gay men has not seen one case of HIV infection since it began in 2012, according to the first “real world” evaluation of the regimen at Kaiser Permanente San Francisco Medical Center. [More]
Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection--an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing. [More]
US health care providers reluctant to prescribe HIV prevention plan

US health care providers reluctant to prescribe HIV prevention plan

Many health care providers across the United States may be reluctant to prescribe an increasingly important prevention approach to some of their patients who are at substantial ongoing risk for HIV. [More]
HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV. [More]
NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN). [More]
Dosing of antiretroviral medication to prevent HIV infection differs by sex

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. [More]
Viewpoints: Many beneficiaries of health law don't vote; reboot for healthcare.gov

Viewpoints: Many beneficiaries of health law don't vote; reboot for healthcare.gov

For starters, my strong hunch from my own reporting in the region over the past couple years-;including several trips to Kentucky for a new book on McConnell-;is that the Democrats' biggest problem in Appalachia and the Upland South is not that the people who are benefitting from Obamacare or would stand to benefit from it if their states fully implemented the law are voting against their own interests, for Republicans. [More]
First Edition: August 12, 2014

First Edition: August 12, 2014

Today's headlines include stories about how the federal government's experience with healthcare.gov has led to the creation of the U.S. Digital Service. [More]
State highlights: Va. Lt. Gov.'s politics and pediatrics juggle; Md. hospital error reporting; ruling on Fla. 'Docs V. Glocks' law

State highlights: Va. Lt. Gov.'s politics and pediatrics juggle; Md. hospital error reporting; ruling on Fla. 'Docs V. Glocks' law

A selection of health policy news from Virginia, Maryland, Florida, New York, Wisconsin, Washington state, New Jersey and Kansas. [More]
Longer looks: the economics of infertility; placebos as treatment raises ethical dilemmas

Longer looks: the economics of infertility; placebos as treatment raises ethical dilemmas

About a decade ago, Medicaid programs were struggling to keep up with skyrocketing prescription drug costs. Between 1997 and 2002, drug spending in the program for low-income Americans grew by about 20 percent annually. ... Medicaid directors began looking for ways to tamp down on those costs. One of the most popular policies was something called "prior authorization" for a new wave of more expensive, anti-psychotic drugs ,... These policies, in a sense, worked: they helped rein in how much Medicaid spent filling prescriptions. But in another sense, they may not have worked at all: a growing body of research has begun questioning whether restricting drug spending may have just shifted costs elsewhere -; particularly, into the prison system (Sarah Kliff, 7/22). [More]
State highlights: Iowa invests in autism program; rural docs feel the pinch of Wisconsin's low Medicaid payments

State highlights: Iowa invests in autism program; rural docs feel the pinch of Wisconsin's low Medicaid payments

A selection of health policy stories from New York, Missouri, Texas, Massachusetts, Maine, Georgia and Pennsylvania. [More]
First Edition: July 14, 2014

First Edition: July 14, 2014

Today's headlines include coverage of Medicare, the health law and veterans' care policy issues as well as reports from the campaign trail. [More]
Advertisement